

# Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial

**Wednesday, April 4, 2018**

James Heller, vice chair of the firm's Commercial Litigation Department and chair of the firm's Products Liability Practice, was quoted in *Law360*'s "Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial." After a \$28 million verdict in a bellwether Xarelto case in Philadelphia was axed over testimony that additional warnings about the drug's bleeding risks wouldn't have changed a doctor's prescribing decision, attorneys say the plaintiff in a second trial set to begin Thursday will face a challenge ensuring similar testimony doesn't derail his case. Judge Michael Erdos threw out the \$28 million verdict, the first that plaintiffs have managed to win across four Xarelto-related product liability trials in state and federal court against a pair of Bayer AG and Johnson & Johnson units, in January based on testimony from a prescribing physician that she had known about the risks of the drug and would have prescribed it anyway even if stronger warnings had been provided. "The judge now has a history and a precedent that each side knows about, so this doctor is front and center and is going to be the highlight of the trial," Jim said.

To read the full article, [click here](#).

## Related Practice Areas

- Commercial Litigation
- Litigation
- Products Liability